Akebia Therapeutics Inc (AKBA): Debt to Book Capitalization Ratio

The price action history of Akebia Therapeutics (AKBA) illustrates the struggle for market positioning in the anemia drug segment following the approval of its flagship product. The current metric stands at 8.59. Business profitability relies on the commercial launch of Vafseo, Medicare insurance coverage, and royalties. To mitigate risks, Akebia Therapeutics (AKBA) is developing therapies for chronic kidney diseases, supplying clinics with critical medications.

For the pharmaceutical business of Akebia Therapeutics (AKBA), which generates predictable cash flows from renal anemia treatments, this indicator serves as a measure of financial autonomy and resilience to market shocks. The financial leverage ratio based on book capitalization compares total liabilities to equity, demonstrating the company's degree of dependence on external borrowings and determining the actual margin of safety for its assets.